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Abstract 
Background: Institutional data from the Mayo Clinic in Rochester Minnesota shows that the 
blood transfusion rate is twice the national average, and is implemented in a non-standardized 
fashion. Blood transfusions pose many risks to critically ill patients. The aim of this quality 
improvement project was to answer the research question: What are the effects of utilizing Lean 
Six Sigma (LSS) methodology and evidence-based interventions to standardize the blood 
transfusion practices, and decrease blood transfusion rates, for women undergoing cytoreduction 
surgery for ovarian and endometrial cancer at a large academic hospital?  
Methods: The Define, Measure, Analyze, Improve, and Control framework, adopted from LSS 
quality improvement methods, was applied in this study. A root cause analysis conducted in the 
study setting, identified reasons why patients were over-transfused. A literature review was 
conducted to identify evidence-based interventions. Education was provided to the department of 
gynecology oncology surgery, anesthesia and nursing staff in the study setting. The 
multidisciplinary team implemented the following interventions; follow updated institution wide 
transfusion guidelines, communicate between the anesthesia provider and surgeon every 500 mL 
of fluid in the suction canister, utilize the hemostasis checklist, and administer a Tranexamic acid 
(TA) 15mg/kg one time dose in the operating room (OR), prior to incision for patients who met 
criteria.  
Results: A total of 184 cases in the pre-implementation group identified in a retrospective chart 
audit, and 89 cases in the post-implementation group that met the study criteria, were 
investigated. Overall, the blood transfusion rate in the post-implementation group was decreased 
by 56.4% (p<0.001), and the number of packed red blood cells (pRBCs) transfused, decreased 
from 169 units to 39 units (p<0.0023). The number of intraoperative pRBCs significantly 
decreased from 148 units in the pre-implementation group, to 33 units post-implementation 
(p<0.001). 60.7% of women received TA. The rate of over-transfusion remained at 43% in both 
cohorts. There was a significant decrease in readmission rates (p<0.002) for the post-
implementation group.  
Conclusions: Lean Six Sigma, multidisciplinary teamwork, and evidence based interventions 
can significantly decrease blood transfusion rates, and the number of packed RBCs transfused, 
without increasing negative outcomes for patients. This quality improvement project 
demonstrated that Tranexamic Acid can be administered for gynecologic oncology surgeries 
without causing adverse effects, in women with ovarian or endometrial cancer. Results of this 
project suggest that efforts to decrease the over-transfusion rate should focus on transfusing 
pRBCs in single units, and limiting transfusions for hemoglobin >7g/dl.  
Data Sources: PubMed, Embase, and CINAHL were utilized for the literature review.  
Keywords: blood transfusion guidelines, Tranexamic acid, cytoreduction surgery, ovarian 
carcinoma, blood transfusions, process improvement, Lean Six Sigma  




A blood transfusion is not a benign intervention. Clinicians must weigh the risks and 
benefits for every patient. Blood therapy is given in order to increase blood volume, increase 
blood flow or improve oxygen transportation.1 However, blood transfusions carry risks for 
negative side effects, are a limited and costly resource, and not everyone is willing to receive 
blood. 
Blood transfusions have the potential to cause numerous adverse effects. Complications 
can include acute lung injury, transfusion-transmitted infection, venous thromboembolism, 
immunomodulation, circulatory overload, and mortality.2-4 Blood transfusions present specific 
risks for patients with cancer. Individuals with cancer are at a greater risk for developing 
infections and cancer recurrence, secondary to transfusion-related immunomodulation.5,6 
According to the National Blood Collection and Utilization Report,2 the gap between the 
supply and demand for blood is increasing. Supply of packed red blood cells (PRBCs) through 
autologous donations is declining significantly. Compared to 17.3 million units collected in 
2008, whole blood and red blood cell collection decreased 9.1% to 15.7 million units in 2011.2 
Approximately 13.1 million units of packed red blood cells (PRBC) are transfused every year.2,7 
Hospital expenses for blood and associated handling costs are increasing while 
reimbursement rates are falling. On average, a hospital pays $225.42 for one unit of leukocyte 
reduced red blood cells.2,8 This cost is a slight increase from the 2008 National Blood Collection 
and Utilization survey and does not include laboratory or supply costs.2 The American 
Association of Blood Banks (AABB) projects a decline in reimbursement by 55% for a majority 
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of the laboratory and supply costs associated with processing, handling, and storing a unit of 
packed red blood cells.9   
In 2013, the Centers for Medicare and Medicaid Services (CMS) initiated hospital value-
based purchasing in an effort to improve the quality of healthcare.10 The initiative allows CMS to 
pay hospitals based on the quality of care provided. As of 2011, CMS reimbursed approximately 
86.4% of the cost of a unit of packed red blood cells (PRBCs).2 Reimbursement rates from CMS 
can fluctuate according to set quality metrics such as blood transfusions and related outcomes. 
Blood transfusions can lead to increased cost for hospitals and patients, poor outcomes and less 
reimbursement from CMS.  
Lean Six Sigma (LSS) has been a long-standing quality improvement methodology. Most 
people relate to Lean with Toyota’s great success in the 1980’s.11 Lean is a holistic approach to 
continuous improvement. Lean eliminates waste, engages personnel, advocates for patient and 
staff satisfaction, and promotes a high quality of care.11 Hospital case studies have been 
presented to show that LSS is successfully utilized in healthcare. Mayo Clinic, ThedaCare and 
New York City Health and Hospitals Corporation, are among several hospitals that have 
implemented and sustained LSS for several years.11-13 LSS methodology has helped hospitals 
decrease infection rates,14 increase operating room (OR) efficiency,13 and increase safety 
outcomes.15  
Mayo Clinic Rochester has a higher incidence of blood transfusions compared to the 
national average in procedures for gynecological malignancies. Institutional data shows the 
blood transfusion rate from 2004-2010 was 57.3%. The transfusion process is approached in a 
non-standardized fashion, and could potentially increase the risk of mortality and cancer 
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recurrence in patients with ovarian cancer.16 The high transfusion rate could negatively impact 
reimbursement with the adoption of value-based purchasing and carries the potential for negative 
patient outcomes.  
The purpose of this project is to examine the relationship between standardizing a blood 
transfusion practice utilizing LSS and evidence-based interventions, and the effect this has on the 
blood transfusion rates in women undergoing open procedures for ovarian or endometrial 
cancer. This will be accomplished by answering the research question:  What are the effects of 
utilizing Lean Six Sigma methodology and evidence-based interventions to standardize blood 
transfusion practices, and decrease blood transfusion rates, for women undergoing cytoreduction 
surgery for ovarian and endometrial cancer, at a large academic hospital? 
Literature Review 
Increasing economic demands, along with the desire to utilize best practice to optimize 
patient outcomes, require hospitals to investigate strategies to reduce unnecessary blood 
transfusions. Patient blood management (PBM) has become a highlighted topic, brought forth by 
the United States Department of Health and Humans 2011 National Blood Collection and 
Utilization Survey.2 Patient blood management incorporates all aspects of patient evaluation and 
decision-making processes in regard to transfusions with the intent of reaching the best possible 
outcomes for every individual.2  
Hospitals that run a PBM program provide education to staff and implement interventions 
to optimize a patient’s hemoglobin level and minimize blood loss. Interventions such as enteral 
and parenteral iron replacement, Erythropoietin injection, intraoperative blood salvage, 
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Tranexamic Acid administration, and Lean Six Sigma have been examined and have been shown 
to be beneficial in specific situations.3 A literature review was performed for the years 2011-
2016 to examine strategies that could be implemented in the perioperative period to potentially 
reduce blood transfusions in women undergoing open procedures for gynecological 
malignancies.  
Current Transfusion Guidelines 
 
Several transfusion guidelines exist in the medical literature. The Society of Thoracic 
Surgeons (STS) formulates evidence-based patient blood management recommendations for the 
cardiothoracic patient population.16 The American Society of Anesthesiologists (ASA) write  
recommendations based  on scientific evidence to provide guidelines for perioperative patients.17 
The Society of Critical Care Medicine (SCCM) offers transfusion recommendations for critically 
ill and trauma patients.18 The American Association of Blood Banks (AABB) publishes general 
transfusion guidelines for all clinical practitioners.19  
There are some commonalities found amongst the pre-existing guidelines. All 
organizations recommend not transfusing solely based on a trigger hemoglobin level. Instead, 
transfuse a patient based on the entire hemodynamic picture.16-19 Clinicians should evaluate and 
consider patient-related factors such as age, comorbidities, amount of blood loss, and risk for 
ischemia in the decision-making process.1, 16-19 All of the existing guidelines recommend a blood 
transfusion at a hemoglobin level less than 6g/dl, rarely transfuse at hemoglobin greater than 
10g/dl, and leave ambiguity for hemoglobin levels between 6-10 g/dl.16-19  
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Restrictive  blood  transfusion  practice 
 Blood products are a life-saving but limited resource. Blood transfusions have been 
identified as, “one of the top five most frequently overused therapeutic procedures in the United 
States”.20(pg.2753) Blood transfusions have the potential to increase morbidity and mortality in 
critically ill and surgical patients.1,4,21,22 One unit of pRBCs significantly increases the risk of 30-
day mortality, morbidity, pneumonia, and sepsis.22 Transfusing two units of pRBCs significantly 
increases these risks as well as surgical site infection.22 Therefore, pRBCs should be transfused 
one unit at a time.  
In 1990, the transfusion requirements in critical care (TRICC) trial demonstrated that a 
restrictive blood transfusion practice significantly decreased mortality in patients without cardiac 
disease.23 Following the TRICC trial, Carless et al. confirmed that a restrictive blood transfusion 
practice does not increase the rates of cardiac events, pneumonia, thromboembolism, and 
mortality.24 The current evidence recommends a transfusion trigger hemoglobin of 7 g/dl in a 
patient without cardiac disease.18-20,23-25 Restrictive blood transfusion policies are safe for 
critically ill patients and should be considered for women undergoing surgery for ovarian cancer.  
Patient Blood Management Interventions 
Anemia is a significant problem for individuals with ovarian or endometrial cancer. Low 
hemoglobin levels are associated with decreased functional capacity, poor quality of life, cancer 
recurrence, and death.26,27 Anemia is a leading risk factor for a blood transfusion.28 The rate of 
anemia has been found to be as high as 95% in women with ovarian cancer who have also 
received neoadjuvant chemotherapy.26  Women undergoing surgery for advanced stage ovarian 
cancer are at risk for severe bleeding related to the length of procedure, tumor biology, 
neoadjuvant chemotherapy or radiation, and complexity of the procedure.29 The high incidence 
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of pre-operative anemia, along with the risks associated with surgery, emphasize the importance 
of addressing interventions to potentially decrease a high blood transfusion rate.    
Erythropoiesis-stimulating agents and iron supplementation 
Erythropoiesis-stimulating agents (ESAs) are an effective pharmacologic intervention to 
increase hemoglobin levels for patients with chronic kidney disease, those undergoing high 
blood loss surgeries, and those receiving myelosuppressive chemotherapy.28 Erythropoietin has 
been shown to be highly effective in increasing hemoglobin levels and has been known to 
produce the equivalent of 1 unit of blood per week of treatment.30 Erythropoietin is especially 
effective in cancer patients when it is administered with iron therapy.28 As with every 
intervention, providers should weigh the risks and the benefits for every individual.  
Cancer patients are susceptible to complications from ESAs. The most common 
complications are increased mortality rate and increased risk of thromboembolic events.31-34 
Erythropoietin has been shown to increase mortality by 10%.32 ESAs significantly increase the 
risk of cancer recurrence and death in patients with ovarian cancer.31 Currently, Erythropoietin 
has a black box warning to alert providers of the serious risks associated with the use of ESAs in 
patients with cancer.35  
Not only is the administration of ESAs potentially hazardous, but also time-consuming to 
reach a therapeutic effect.  Erythropoietin and iron therapy require weeks to achieve the best 
results.35 Gynecology-oncology surgeons, at the Mayo Clinic in Rochester, offer women with 
ovarian cancer next day surgery. This is an enormous satisfier for patients. Next day surgery 
does not allow for the time that is required of iron supplementation and Epoetin.  
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There are only two current studies in the literature that address benefits and risks of ESAs 
in cancer patients.31,33 Neither of the studies discuss perioperative use and outcomes of 
Erythropoietin in ovarian cancer patients. The documented negative outcomes, along with 
limited research available, prevent the use of Erythropoietin in practice in an attempt to improve 
perioperative blood transfusion rates for women undergoing open surgical procedures for 
malignant gynecological tumors.   
Intraoperative blood salvage 
Intraoperative blood salvage (IBS) involves the collection, filtration, washing, and 
administration of shed blood during surgery.36 A variety of surgical specialties, especially 
orthopedic and cardiac surgery, utilize IBS as a cost-effective and safe method to reduce the rate 
of allogenic blood transfusions.37 IBS has been shown to decrease the requirement for allogenic 
blood transfusions by 38%.38 The use of IBS in patients with cancer has been a controversial 
topic for decades. The hesitancy to use IBS with cancer patients stems from one case study 
published in 1975.39 As a result of this case report, providers conclude that administration of 
salvaged blood during surgery in a patient with cancer would lead to diffuse metastases of 
cancer.   
Numerous studies have since been performed on the topic of IBS and its role in cancer 
surgery. There are two interventions that can make IBS safer for the patient with cancer. The 
type of filter used in the blood salvage machine can impact how well cancer cells are removed. 
Evidence advocates for the use of leukocyte depletion filters.37,40-42 Leukocyte depletion filters 
are effective in the removal of tumor cells and do not increase the risk of cancer recurrence.40-42 
Another recommended intervention is the practice of irradiating salvaged blood prior to 
administrating the blood to the patient.43 
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Cell saver has been studied in patients with prostate adenocarcinoma, hepatocellular 
carcinoma, cervical, and spine cancer. All of the studies suggest that IBS is safe to use on 
patients with cancer.36,40,44-50 None of the studies show that IBS causes metastatic disease. 36,40,44-
50 Research in the surgical specialty of gynecology oncology surgery is limited to cervical 
cancer. Studies on the use of IBS in high blood loss procedures for ovarian cancer are 
nonexistent. Also, the research done on liver, spine, cervical, and prostate cancer are 
retrospective chart reviews or prospective cohort studies. 30,34,38-44 There is no strong evidence to 
support the use of IBS in ovarian cancer surgery.  
Antifibrinolytics 
 Tranexamic acid (TA) is a synthetic amino acid that inhibits plasminogen activation. 
Tranexamic acid was introduced into practice more than 40 years ago, and has been used in a 
variety of surgical settings to reduce the amount of blood loss, and blood transfusions 
administered to patients.51 Tranexamic acid is the antifibrinolytic of choice in the perioperative 
period.28 Several, recent studies support the efficacy of TA in an array of surgical settings 
including cardiac,52 orthopedic,53,54 trauma, 55,56, and plastics.57 No serious adverse events have 
been reported as a result of TA administration.55,56,58  
Venous thromboembolism 
In comparison to other patient populations, patients with cancer are at risk for venous 
thromboembolic (VTE) events. Most recent data suggests a VTE rate of 16% in women 
diagnosed and treated for ovarian cancer.59 A venous thromboembolic event can be a dangerous 
complication. VTE is the leading cause of death in patients receiving chemotherapy.60,61 Intra-
operative interventions such as low molecular weight Heparin and intermittent sequential 
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compression devices can be applied to provide prophylactic prevention of a VTE. Despite 
documented interventions, VTE rates remain high in patients with cancer receiving 
chemotherapy.59,61 
Three randomized control trials (RCTs) have examined the effects of Tranexamic acid 
administration in cancer patients; breast, prostate and ovarian.51,62,63  A randomized double-blind, 
placebo-controlled study showed that TA can be effective in significantly reducing blood loss 
and blood transfusions in this population.51 The dose of TA was 15mg/kg administered one-time 
prior to incision.51 The VTE rate was 7% with a majority of them occurring in the placebo 
group.51 Tranexamic acid has been shown to be safe, free from adverse effects while decreasing 
blood loss and intraoperative blood transfusions in a multitude of surgical specialties, including 
procedures for advanced ovarian cancer.51,58  
Programs to reduce blood transfusions 
The pressure to conserve blood, improve quality of care, and increase hospital revenue 
has required hospitals to examine their blood transfusion practices. In 2007, the University of 
Alabama at Birmingham implemented a restrictive blood transfusion policy for patients 
undergoing surgery for gynecologic malignancies.64 The transfusion initiative consisted of two 
guidelines: no pRBC transfusion until the hemoglobin drops below 7g/dl, and transfusions were 
to be administered one unit at a time.64  Clinicians were required to document the indication for 
transfusion. Gynecologic oncologists tended to transfuse two units of pRBCs at a time despite 
the guidelines. The overall compliance rate was 81.1%, but only 64.7% of the transfusions were 
administered one unit at a time.64 There was no significant difference in infection rates, 
thrombotic events, and mortality between the compliant and noncompliant transfusions.64 The 
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results of this retrospective chart review suggest that a restrictive blood transfusion practice is 
safe in patients undergoing surgery for ovarian cancer. 
 A prospective study looked at the appropriateness of perioperative blood transfusions in 
undergoing cancer surgery. Over-transfusion was defined as a postoperative hemoglobin 
exceeding 10g/dl.65 Based on this criterion, more than half of patients were over-transfused. The 
rate of  over-transfusion was highest in patients who received two units of pRBCs.65  
 New York Methodist Hospital (NYMH) implemented a monitoring program to ensure the 
appropriateness of blood transfusions based on current evidence. The program was a 
multidisciplinary effort. The protocol allowed for one unit of pRBCs to be made available for 
patients with a hemoglobin greater than 7g/dl, and two units of pRBCs if hemoglobin was less 
than 6g/dl.5 Physicians were required to document and justify the need for blood. If the blood 
bank technologist discovered that the requests did not meet the protocol criteria, the request was 
sent to a departmental reviewer. This process emphasized patient safety.5 The program was 
monitored for two years following implementation. The blood transfusion rate decreased 33.2% 
in the first year and 38.1% in the second year.5 The decrease in transfusion rates reduced the 
complication rates and cost of blood products.5 
 Several hospitals have had success in implementing different interventions to reduce the 
rates and increase the appropriateness of blood transfusions.5,64,65 Restrictive transfusion policies, 
monitoring programs, and transfusion of one unit of pRBCs at a time have resulted in decreased 
complications, increased appropriateness of transfusions, and costs savings to the hospital. 
Women undergoing debulking surgery could benefit from similar interventions in a large 
academic hospital.   
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Lean Six Sigma 
Lean and Six Sigma are quality improvement methodologies that have been around since 
the late 1980’s. Lean is a patient-centered process which emphasizes supporting the mission of 
the organization, utilizing the capabilities of individuals, adding value, and correcting existing 
system problems.11 Six Sigma is designed to identify and correct the causes of errors.15 A higher 
level of sigma is equivalent to a higher level of quality.66 Six Sigma encompasses a five-stage 
process: Define, Measure, Analyze, Improve and Control (DMAIC).15 Six Sigma provides the 
statistical rigor while Lean results in the reduction of waste in a process. Together, LSS can 
improve the quality of care, increase customer satisfaction, decrease costs, and increase 
revenue.15  
Lean and Six Sigma principles complement each other. They have been used 
simultaneously in healthcare since 1998.15 Implementation of quality improvement (QI) 
methodologies has aided healthcare professionals in the quest to provide exceptional patient care. 
Significant improvements have been made across outpatient, inpatient, and operating room 
settings. LSS has been successfully utilized in healthcare to improve operating room efficiency, 
optimize the patient experience, decrease operation complications, decrease patient infection 
rates, and decrease mortality.15 Specifically, in the perioperative setting, LSS has shown 
significant improvement in patient care through increasing operating room efficiency and 
decreasing mortality.13,67,68 
There are no randomized control trials related to the use of LSS in the operating room 
environment. However, specific studies have shown that LSS can contribute to significant 
improvements in patient care and the function of an organization. The noteworthy successes of 
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LSS suggest there is a place for the use of LSS in improving the patient experience, decreasing 
cost, and decreasing negative patient outcomes.  
Patient blood management is a topic undergoing intense scrutiny. Researchers are 
advocating for the conservation of a valuable resource with the goal of optimizing patient 
outcomes and increasing hospital revenue. Surgical patients with advanced ovarian or 
endometrial cancer present with unique risks. They are often anemic from neoadjuvant 
chemotherapy, undergoing procedures that could result in a large amount of blood loss, and are 
susceptible to cancer recurrence along with thromboembolic events.  
Current guidelines support the use of a restrictive blood transfusion policy and the 
transfusion of one unit at a time for stable patients undergoing open procedures for ovarian, 
therefore, should not be implemented in this quality improvement project. Tranexamic Acid has 
been shown to be a safe and effective intervention in gynecologic oncology procedures. Lean Six 
Sigma methodology has shown success when utilized in the health care setting. There are no 
studies in which LSS was utilized to decrease a blood transfusion rate in gynecology-oncology 
surgery.  
This study attempts to answer the following question: What are the effects of utilizing 
Lean Six Sigma methodology and evidence-based interventions to standardize blood transfusion 
practices, and decrease blood transfusion rates, for women undergoing cytoreduction surgery for 
ovarian and endometrial cancer, at a large academic hospital? 
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Methodology 
 Doctors Bradley Narr (Chair of the Department of Anesthesia and Perioperative 
Medicine), Bobbie Gostout (Chair of the Department of Gynecology Surgery), and Ann Sullivan 
(CRNA supervisor), supported the investigation of the research question at Mayo Clinic, 
Rochester, Minnesota. This quality improvement project was a multi-disciplinary effort. The 
steering team consisted of Sumer Wallace, MD, Christopher Jankowski, MD, Sean Dowdy, MD, 
Jamie Bakkum-Gamez, MD and Jessica Halverson, CRNA. The team attended the Academy of 
Excellence in Healthcare at The Ohio State University Fisher College of Business, where they 
underwent extensive training in LSS principles and applied knowledge gained to this project. 
This continuous improvement project offered high-payback in the form of cost savings, patient 
outcomes, and encouraging multidisciplinary collaboration.  
Setting 
 The Mayo Clinic Rochester (MCR) is a 2,000 bed, academic medical center located in 
the upper Midwest. Mayo Clinic Rochester is comprised of two hospitals, along with an 
outpatient surgery center. There are approximately 87 operating rooms between the two 
campuses: Rochester Methodist Hospital (RMH) and Saint Marys Hospital. The gynecology- 
oncology operating rooms are located on the RMH campus. Mayo Clinic, Rochester, Minnesota 
IRB and the University of Michigan, Flint IRB approved this project as exempt because it is a 
quality improvement study.  
Study Design  
 The quality improvement project was approached using LSS strategies. The framework 
for the study was define, measure, analyze, improve, and control (DMAIC). DMAIC is a five 
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step data-driven process improvement tool utilized in continuous improvement.69 The conceptual 




 The define phase involves identifying the problem, setting a goal, and establishing the 
project timeline. The steering team identified the problem and the current status of Mayo Clinic’s 
transfusion rate in gynecology-oncology surgery. The team proposed a goal of 30% reduction in 
blood transfusion rates in women undergoing malignant abdominal surgical procedures. The 
project timeline is embedded in the A3 as shown in Appendix A.   





Use Lean Six Sigma methodologies to examine 
and improve the current blood transfuson 
process for women undergoing ovarain cancer 
staging surgery, pelvic exoneration, open 
procedure for stage III/IV endometrial cancer 
or intraoperative radiation therapy.  
Process flow mapping of the patient process 
to identify where improvements need to be 
made. Perform a root cause analysis through 
5 Why mapping on patients who were over 
transfused intraoperatively and 
postoperatively based on postoperative 
hemoglobin values. Create countermeasures 






Mayo Clinic Rochester’s 
blood transfusion rate in 
this population is 10.5%, 
whereas the national rate, 




(2013), is 5.1%.  Also, 74 
% of the blood 
transfusions occur 
intraoperatively and within 
the first 48 hours 
Extensive review of 
literature regarding Lean 
methodologies in 
healthcare, best practice 
guidelines for blood 
transfusions,  and 
Tranexamic Acid use in 
gynecology surgery. 
Number of units of pRBCs transfused
Pre and post transfusion hemoglobins
Blood Transfusion rate
Postoperative Hemoglobin
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 The steering team established that an intraoperative transfusion would be any transfusion 
administered intraoperatively through the post-anesthesia care unit (PACU) stay. A postoperative 
transfusion is one that occurs from the time the patient leaves the PACU through 48 hours 
postoperative. The post-transfusion hemoglobin goal for this population is 8.5-9.5g/dl.  
Measure 
 The purpose of the measure phase is to establish baseline data. Institutional data shows 
the blood transfusion rate from 2013-2014 was 56%. Further investigation of data showed 
investigators that open malignant abdominal procedures account for 57% of blood transfusions in 
the gynecology surgery department. Data pulled from 2010-2014 disclosed that the majority of 
blood transfusions in gynecologic oncology surgery occurred during the intraoperative and 
immediate forty-eight hours postoperative phases. The data obtained allowed researchers to 
determine where to focus efforts in order to make the largest impact on high blood transfusion 
rates.  
Analyze 
 The current blood transfusion process was analyzed by developing a flow map, otherwise 
known as a swim lane map. Appendix B depicts the standard flow of the perioperative 
transfusion process. The process map allowed the team to identify areas of opportunity for 
improvement.  
 The process map highlighted ambiguity surrounding the blood transfusion process, 
specifically during the intraoperative and postoperative period (Appendix B). Following this 
discovery, the team performed a “5 Why” root cause analysis. The analysis was performed by 
mapping the process on individual patients who were over-transfused intraoperatively, 
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postoperatively, or both based on postoperative hemoglobin of 9.5 g/dl. The root cause maps 
allowed researchers to follow the flow of patient management intraoperatively and 
postoperatively. Appendix C illustrates an example of an intraoperative “5 Why” cause map. 
Appendix D depicts an example of a postoperative “5 Why” cause map.  The cause maps 
provided clarity and revealed that patients were over-transfused for the following reasons:  
 large academic center with many learners along with no standardized guidelines 
 pRBCs were administered two units at a time 
 trigger hemoglobin was higher than evidence suggests it should be 
 debulking and malignant abdominal surgeries are complex, long cases resulting in 
a large amount of blood loss and fluid volume shifts 
Improve/Implementation 
In response to the root cause analysis, the team created countermeasures with the intent to 
improve the process, to decrease blood transfusion rates, and to improve patient care. The first 
countermeasure was created with the goal of decreasing blood loss: administration of TA. 
Tranexamic acid has been studied vigorously and is being utilized in many other surgical 
specialties.51-57 A study performed by Lundin et al. supports the safety and efficacy of the use of 
TA in gynecology-oncology surgical patients.51 The gynecology-oncology providers assessed the 
patient for exclusion criteria in the prescreening clinic. The exclusion criteria can be seen in 
Table 1. When a patient was a candidate for TA, the surgical team ordered the infusion the 
evening before surgery. Tranexamic Acid is administered in the operating room prior to incision 
in a one-time dose of 15ml/kg. To assure patient safety, the incidence of VTE was monitored 
continuously by the gynecology-oncology surgical team.  
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Table 1. Exclusion Criteria for Tranexamic Acid  
1. Treatment with anticoagulation in the last month 
2. Allergy to TA 
3. History of present lab signs of bleeding 
disorder, coagulopathy, or thromboembolic state 
4. History of MI in the last year 
5. Present unstable angina or severe CAD 
6. Reduced renal function (creatinine >2.5) 
7. Acquired defective color vision 
 
A group of countermeasures was created to address communication in the operating room 
(OR). All providers in the operating room stopped at critical junctures during the operation to 
discuss current blood loss and status of the surgery. This communication occurred when there 
was at least five hundred milliliters of fluid (blood, ascites, etc.) in the suction canister. During 
this hard stop, the multidisciplinary team discussed the phase of the surgery and hemostasis of 
the surgical field.  
 The gynecology-oncology surgeons created a hemostasis checklist to improve 
communication, and identify a checkpoint at which the surgeon examined the abdomen for any 
sign of active bleeding. The hemostasis list was a hard stop prior to closing the surgical wound. 
The circulating registered nurse (R.N.) called out each site, and the surgeon examined said site 
and affirmed hemostasis.  
 Concurrently with this project, Dr. Kor developed an institution-wide transfusion 
guideline supported by best practice.1,17,64 The blood transfusion guideline made the following 
recommendations:  
 RBC transfusion should be considered if Hb <7 g/dL,  
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 RBC transfusion may be beneficial in patients with acute coronary syndrome with 
Hb ≤ 8 g/dL,  
 Hemoglobin concentration ≤8 g/dL with symptoms thought to be related to 
anemia, including:  
o Hypotension unresponsive to fluid resuscitation 
o Unexplained tachycardia unresponsive to fluid resuscitation 
o Cardiac chest pain  
o Congestive heart failure  
 Following development of countermeasures, the steering team educated staff and learners 
throughout the department of anesthesia, the department of gynecology surgery, and the 
department of nursing. The education was in the form of presentations at several staff, quality 
improvement, and department meetings. The entire process for this quality improvement project 
was compiled into an A3 (Appendix A). Project implementation occurred on September 28, 
2015.  
Control 
Following International Review Board (IRB) approval at Mayo Clinic, Rochester 
Minnesota, and University of Michigan, Flint, a quantitative, retrospective chart review of 
gynecologic-oncology patients was performed. A quantitative study was selected because the 
study was carefully designed prior to the data collection. A data collection tool was utilized to 
collect hard data in the form of numbers and statistics. Subsequently, adult women scheduled to 
undergo a laparotomy procedure for ovarian or endometrial cancer were included in the pre-
implementation group for this study. 
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Permission to review the patient’s electronic medical record (EMR) was obtained on all 
patients entering the Mayo Clinic health system and documented electronically. Charts were 
reviewed for all gynecology-oncology patients who met inclusion criteria. The pre-
implementation cohort included patents who had a laparotomy procedure for ovarian or 
endometrial cancer between September 1, 2014 and September 25, 2015. The post-
implementation cohort included patients having a laparotomy procedure for ovarian or 
endometrial cancer after September 27, 2015 through March 30, 2016.  
Abstracted data included patient demographics, cancer type and stage, surgical 
procedure, pre-operative hemoglobin, postoperative hemoglobin, number of packed red blood 
cells (pRBC) units transfused, where the transfusion occurred (intraoperative, postoperative), 
estimated intraoperative blood loss, if TA was administered, if the transfusion was appropriate 
based on new guidelines, length of surgery, postoperative complications, and 30 day mortality. 
The data was collected and placed in an excel spreadsheet (Appendix E). The data collection tool 
was saved on a private computer drive in the Mayo Clinic server.  
Results 
 A total of 184 women were included in the pre-implementation group, and 89 women in 
the post-implementation group in this project. Demographic and surgical variables are outlined 
in Table 2. The mean age for the pre-implementation cohort was 62.4 years and 64.0 years for 
the post-implementation cohort. Ovarian cancer (82.6% and 83.1%) was the most common 
diagnosis in both groups. A majority (83%) of patients in both cohorts had advanced stage or 
recurrent cancer. A majority (98%) of women in both cohorts were ASA II or III. Within the 
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surgical variables, there was a decrease in operative time from 279.3 to 241.7 minutes (p=0.01) 








Age, Mean(SD) 62.4 (12.4) 64 (11.6) 0.32 
BMI (kg/m2), Mean (SD) 28.7 (7.7) 29.2 (7.9) 0.62 
ASA score    
I 3 (1.6%) 2 (2.2%)  
II 107 (58.3%) 41 (46.1%)  
III 74 (40.2%) 46 (51.7%)  
Prior history of VTE 19 (10.3%) 7 (7.9%) 0.52 
Current tobacco use 13 (7.1%) 12 (13.5) 0.08 
Cardiovascular disease 59 (32.1%) 38 (42.7%) 0.08 
EBL (mL), Median (IQR) 500 (250,800) 300 (200, 600) 0.009 
Operative time (min), Mean (SD) 279.3 (118.6) 241.7 (105.6) 0.01 
Diagnosis   0.91 
   Ovarian cancer 152 (82.6%) 74 (83.1%)  
   Endometrial cancer 32 (17.4%) 15 (16.9%)  
Stage   0.50 
   I-II 31 (16.8%) 15 (16.9%)  
   III-IV 107 (58.2%) 46 (51.7%)  
   Recurrent 46 (25.0%) 28 (31.5%)  
Presence of ascites 49 (26.6%) 21 923.6%) 0.59 
Volume of ascites (mL), Median 
(IQR) 
1100 (300,2500) 1100 (600, 2000) 0.62 
Length of stay (days), Median 
(IQR) 
4 (3, 6) 4 (3, 6) 0.87 
    
  
Table 2. Demographic, Surgical, and Postoperative Variables in Pre and Post Intervention 
Groups 
Abbreviations: IQR, interquartile range; SD, standard deviation 
Comparisons between cohorts were evaluated using the two-sample t-test for age and BMI, the 
Wilcoxin rank sum test for ASA score, EBL, volume of ascites and length of stay, and the chi-
square or Fisher’s exact test for categorical variables.  
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Blood Transfusion Rates 
Institutional data from the study setting showed the transfusion rate was twice the 
national average, 5.1%, from 2004-2010. The transfusion rate for the year prior to the 
implementation of guideline-based interventions was 41.3%, at the Mayo Clinic. The overall 
blood transfusion rate following the implementation of quality improvement methods and 
evidence-based interventions, was significantly decreased to 18.0% (p<0.001). Intraoperatively, 
the blood transfusion rate significantly decreased from 37.5% to 15.7% (p<0.001). There was a 
reduction in the postoperative transfusion rate from 8.7% to 4.5% (p=0.21). Figure 2 depicts the 
significant reduction in blood transfusion rates overall, in the intra-operative phase, and in the 
post-operative phase of patient care.  
 
Number of Units Transfused 
 Another variable measured in this quality improvement project was the number of packed 
red blood cells transfused. Overall, the number of pRBCs transfused decreased from 169 units to 








Figure 2. Transfusion Rates
Pre Post
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in the pre-implementation group, to 33 units post-implementation (p<0.001). Details of the 
number of units transfused in the perioperative phase and 48 hours postoperative can be seen in 
Table 3.  
Table 3. Number of Packed Red Blood Cell Units Transfused 





Intraoperative Units   
   0 115 (62.5%) 75 (84.3%) 
   1 26 (14.1%) 4 (4.5%) 
   2 21 (11.4%) 6 96.7%) 
   3  10 (5.4%) 3 (3.4%) 
   4 10 (5.4%) 0 (0.0%) 
   5 2 (1.1%) 0 (0.0%) 




   0 168 (91.3%) 85 (95.5%) 
   1 11 (6.0%) 2 (2.2%) 
   2 5 (2.7%) 2 (2.2%) 
 
 
Intra- or Postoperative Units   
   0 108 (58.7%) 73 (82.0%) 
   1 25 (13.6%) 5 (5.6%) 
   2 27 (14.6%) 6 (6.7%) 
   3  12 (6.5%) 3 (3.4%) 
   4  7 (3.8%) 0 (0.0%) 
   5 4 (2.2%) 1 (1.1%) 
   6 1 (0.5%) 0 (0.0%) 
   8 0 (0.0%) 1 (1.1%) 
Tranexamic Acid 
 
 Prior to project implementation, the department of gynecology-oncology did not use 
Tranexamic acid. However, post-implementation, 60.7% of patients received TA based on the 
current evidence-based guidelines. Of the 54 women who received TA, 20.4% also received a 
blood transfusion. There were 35 patients who did not receive TA secondary to meeting 
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exclusion criteria for TA administration as listed in Table 1, surgeon preference, or provider 
unfamiliarity with the protocol. Five patients (14%) who did not receive TA also received a 
blood transfusion.  
Over-transfusions 
 
 Over-transfusions were measured according to best practice transfusion guidelines, the 
department goal of post-operative hemoglobin between 8.5-9.5g/dl, and the number of pRBC 
units transfused at a time. There were three primary reasons for an over-transfusion; a 
transfusion was administered at a higher than recommended trigger hemoglobin, two units were 
transfused at a time, or a patient received two units for a higher than recommended hemoglobin. 
The rate of over-transfused patients remained at 43% for both groups. There was significantly 
more blood loss in patients who were considered over-transfused (p<0.001) in both cohorts.  















Figure 3. Root Causes of Overtransfusions
pre post
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Complications 
 Table 4 illustrates the various complication variables between the pre and post 
implementation groups. The rate of readmission was significantly higher in the pre-
implementation group at 12.5% (p=0.002). There were no other significant differences in 
complications. The VTE rate was monitored throughout the study to ensure safety of TA 
administration. There was no incidence of VTE in patients who received TA.  
Table 4. Comparison of Complications  
Postoperative Complications  







   Readmission 23 (12.5%) 1 (1.1%) 
   Reoperation 8 (4.3%) 0 (0.0%) 
   Infection- Pulmonary 6 (3.3%) 2 (2.2%) 
   Infection- Sepsis 8 (4.3%) 0 (0.0%) 
   Infection- Wound 10 (5.4%) 4 (4.5%) 
   Infection- pelvic Abscess 1 90.5%) 0 (0.0%) 
   Unplanned ICU admit post-op 6 (3.3%) 0 (0.0%) 
   Post-op anastomosis leak 1 (0.5%) 0 (0.0%) 
   Post-op perforation, non-anastomosis leak 1 (0.5%) 0 (0.0%) 
   Small bowel obstruction 1 (0.5%) 0 (0.0%) 
   DVT/PE 3 (1.6%) 1 (1.1%) 
Discussion 
This quality improvement project was a complex process that emphasized 
multidisciplinary teamwork, Lean Six Sigma methodologies, and evidence-based interventions. 
This study shows that multidisciplinary teamwork along with evidence-based guidelines can 
successfully improve patient care. The Department of Gynecologic Oncology Surgery, along 
with the Department of Anesthesia and Perioperative Medicine, at the Mayo Clinic, significantly 
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reduced the blood transfusion rate by 56.4%, and significantly decreased the units of pRBCs 
transfused.  
 Blood is an expensive, scarce resource that when administered to patients, can 
potentially result in negative outcomes such as VTE, longer hospitalization, and mortality.2-4 
Cancer patients are vulnerable to cancer recurrence and infection as a result of blood 
transfusions.6 The negative effects, expense, and scarcity of blood requires hospitals to examine 
transfusion practices in the best interest of patient outcomes and economics.  
Lean Six Sigma provided a framework to define, measure, analyze, improve and control 
the blood transfusion process, for women undergoing open procedures for ovarian or endometrial 
cancer. Lean Six Sigma has been used successfully in healthcare and perioperative care to 
improve the quality of care, increase customer satisfaction, decrease costs, and increase 
revenue.15 Mapping sessions and root cause analysis implemented during this project, allowed 
the team to identify gaps in standardization, and to determine causes for over-transfusion in 
gynecology-oncology surgery.  
Based on the knowledge gained from the measurement and analytic stages of this project, 
the steering team created countermeasures to improve the transfusion process. The team 
recommended staff communications in the operating room following the occurrence of 500mL of 
fluid in the suction canister, and a hemostasis checklist was implemented to be utilized at the end 
of the case. The team provided education amongst several departments regarding the measures to 
standardize the blood transfusion process.  
A literature review provided evidence-based interventions that potentially decrease blood 
transfusion rates. Several studies support the safety and efficacy of restrictive blood transfusion 
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practices in critically ill patients.18-20, 23-25 Current evidence suggests providers can safely 
transfuse for a hemoglobin less than 7g/dl in healthy patients, and 8g/dl in a patient with 
coronary artery disease.18-20, 23-25 The updated, institution-wide, transfusion guidelines 
contributed to the success of this project.  
Another evidence-based countermeasure was the implementation of TA. Prior to this 
study, TA was not utilized in the gynecologic oncology surgery. Lundin et al. showed that TA 
15mg/kg administered once immediately before incision reduces blood loss and transfusion rates, 
in women undergoing surgery for advanced stage ovarian cancer.51 This study demonstrated that 
TA can be utilized in the gynecologic oncology population, without causing adverse effects.51 
The current project reiterates the findings from Lundin et al. in that Tranexamic acid was 
administered at the same dose within thirty minutes prior to incision. Blood transfusion rates 
were significantly decreased to 18% (p<0.001), and blood loss was decreased by 200ml 
(p=0.009). Study findings indicated that there were no negative outcomes related to TA. 
Few studies are published on efforts made to improve blood transfusion processes. New 
York Methodist Hospital established a monitoring program to ensure compliance with 
institutional transfusion guidelines.5 This monitoring program achieved great success in 
decreasing the rate of unnecessary blood transfusions and hospital expense. Another study 
examined the compliance of a restrictive transfusion policy in gynecology-oncology surgery. 
This study showed that a restrictive transfusion recommendation can be implemented in 
gynecologic oncology patients.64 However, it also revealed that improvement could be made to 
administer more blood in single unit increments, and limit transfusions for hemoglobin greater 
than 7g/dl.64  
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Limitations 
 The over-transfusion rate remained high for the institution described in this study, before 
and after implementation of several interventions. A weakness of this study is the inability to 
capture all the factors contributing to the perceived need for a transfusion. Despite the existing 
quality assurance documentation surrounding a blood transfusion at this hospital, other variables 
remain unknown. The rate of over-transfusions may be related to an individual patient’s status 
such as low urine output, position changes, or physiologic responses to the procedure. Clinicians 
in this study were not asked to chart details surrounding their transfusion decision process. 
Examining health care providers’ documentation practices may afford greater insight in the 
management of blood loss. Efforts can be made to address over-transfusion with the intent to 
further reduce the number of units transfused.  
Dissemination 
 The author presented this quality improvement project at the Mayo Clinic Institutional 
Process Improvement meeting on January 22, 2016. The steering team will present this project 
for one continuing education credit at a staff conference open to 300 Certified Registered Nurse 
Anesthetists (CRNAs) on June 5, 2017. On October 3, 2017, the steering team will be attending 
the 43rd Annual Mayo Clinic Seminar for Nurse Anesthetists. The team will be presenting a tale 
titled: “Beyond Enhanced Recovery: Using ERAS Pathways as a Platform for Continuous 
Improvement” 
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Conclusion 
 Despite education and evidence-based countermeasures surrounding current blood 
transfusion recommendations, the rates of over-transfusions remained unchanged at 43% 
between the two cohorts. The rate of blood transfusions that occurred at a higher than 
recommended trigger hemoglobin, increased from 36.3% to 57.0%. There are variables which 
could contribute to the unchanged over-transfusion rate; however, this study did not implement a 
monitoring system or documentation requirement to capture real-time factors that were involved 
in the decision to transfusion at a higher hemoglobin or to transfuse two units of blood at a time. 
This is an area of research that has the potential to further improve the blood transfusion process.  
 Control for long-term sustainment of this work requires monitoring the blood transfusion 
rates, number of pRBCs transfused, and over-transfusion rates. Currently, there is no monitoring 
in place for the variables in this study. The Department of Anesthesiology and Perioperative 
Medicine, along with the Department of Gynecology Surgery, is working on long term 
monitoring of all enhanced recovery pathways and quality improvement interventions.  
 While this project achieved several good outcomes, there is still much that can be learned 
and studied to possibly further improve the blood transfusion process. Define, measure, analyze, 
improve and control (DMAIC) could be applied to the high rate of over-transfusion. This type of 
project would require departmental support again and training in the use of quality improvement 
methodologies.   
 There were several benefits as a result of this project. The design of this study raised 
awareness that, in a large academic center, multidisciplinary efforts can achieve great outcomes 
for our patients. Providers willing to embrace change and advocate for a lean culture made 
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significant improvements in patient care. The education provided prior to implementation raised 
awareness of how to apply quality improvement methodologies to address a clinically relevant 
problem. The process also illustrated the importance of implementing best practice when faced 
with the decision to administer a blood transfusion to a woman with ovarian or endometrial 
cancer.  
Patient blood management is an important topic in today’s healthcare market. Strategies 
such as incorporating a restrictive blood transfusion protocol, addressing problems in the current 
system as identified in a root cause analysis, formulating acceptable countermeasures, and 
establishing sustainability can benefit both the hospital and patient. These strategies significantly 
reduced the overall blood transfusion rate by 56.4% and the intraoperative blood transfusion rate 
by 58.1%.  The countermeasures in this project resulted in a significant decrease in the number 
of pRBCs transfused intraoperatively. This project proves that a multidisciplinary approach, 
when combined with evidence based guidelines and Lean Six Sigma principles, can lead to a 
successful process change in healthcare and ultimately assure clinicians are giving the best 
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Appendix C: Intraoperative Cause Map  
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